Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
BioCryst reports before market open, meaning Day 0 captures the first reaction session when the market opens after results are released, while Day +1 reflects follow-through trading.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-05 | +$0.05 (+0.55%) | $0.87 (9.59%) | +$0.23 (+2.54%) | $0.55 (6.06%) |
| 2026-05-06 | -$0.20 (-2.21%) | $1.13 (12.46%) | +$0.07 (+0.79%) | $0.38 (4.25%) |
| 2026-02-26 | +$0.35 (+4.64%) | $0.61 (8.01%) | +$0.85 (+10.76%) | $0.92 (11.65%) |
| 2025-11-03 | -$0.46 (-6.28%) | $0.51 (6.97%) | -$0.10 (-1.46%) | $0.38 (5.54%) |
| 2025-08-04 | +$0.78 (+9.81%) | $1.04 (13.14%) | -$0.37 (-4.24%) | $0.36 (4.12%) |
| 2025-02-24 | -$0.92 (-9.99%) | $1.01 (10.97%) | -$0.01 (-0.12%) | $0.50 (6.09%) |
| 2024-11-04 | -$1.08 (-12.81%) | $1.12 (13.23%) | -$0.29 (-4.01%) | $0.41 (5.57%) |
| 2024-08-05 | N/A | N/A | N/A | N/A |
| Avg Abs Move | 6.61% | 10.62% | 3.42% | 6.18% |
Historical price behavior around earnings shows average absolute Day 0 moves of 6.61% and Day +1 moves of 3.42%, indicating that BioCryst typically experiences its most significant reaction in the immediate session following results, with more modest follow-through the next day. The Day 0 trading range averages 10.62%, reflecting high intraday volatility as investors digest the results.
Recent earnings have produced mixed directional outcomes: the most recent Q2 2026 report generated a modest 0.55% gain on Day 0 followed by a 2.54% gain on Day +1, while Q1 2026 saw a 2.21% decline on Day 0 that reversed to a small 0.79% gain on Day +1. The largest moves came in earlier periods, with Q3 2025 dropping 6.28% on Day 0 and Q2 2025 surging 9.81%. This pattern suggests that while the stock can move significantly on earnings, the direction is highly dependent on whether results and guidance exceed or disappoint expectations, with no consistent bias toward gains or losses.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 17) |
| Expected Move | $0.26 (2.96%) |
| Expected Range | $8.36 to $8.87 |
| Implied Volatility | 74.17% |
The options market is pricing an expected move of 2.96% for the November 20 expiration, which is notably lower than the stock's historical average Day 0 move of 6.61% around earnings. This suggests options traders are anticipating a more muted reaction to Q3 results compared to BioCryst's typical earnings volatility, possibly reflecting reduced uncertainty after the strong Q2 performance or expectations that results will land closer to consensus estimates.
Part 3: What Analysts Are Saying
Analysts maintain a Buy consensus on BioCryst with an average rating of 4.42 out of 5.0, reflecting strong bullish sentiment. The current breakdown shows 8 strong buy ratings, 1 moderate buy, and 3 hold ratings, with no sell recommendations among the 12 analysts covering the stock. The average price target of $20.27 implies 136.5% upside from the current price of $8.57, with individual targets ranging from a low of $11.00 to a high of $32.00.
Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.42. This stability suggests analysts are maintaining their bullish stance heading into Q3 results, likely waiting to see whether the company can validate the strong Q2 performance before adjusting their views. The wide range in price targets—spanning from $11.00 to $32.00—reflects divergent views on BioCryst's ability to sustain profitability and execute on its commercial and pipeline opportunities, with bulls seeing substantial upside if ORLADEYO growth continues and navenibart progresses, while more conservative analysts price in execution risk and competitive pressures.
Part 4: Technical Picture
BioCryst enters earnings with a 56% Sell signal from the Barchart Technical Opinion, though this represents an improvement from the 72% Sell reading one week ago, indicating some recent stabilization in technical momentum. The signal has held at 56% over the past month, suggesting the stock has been consolidating after earlier weakness.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains slightly negative heading into earnings
- Medium-term (100% Sell): Strong sell signal suggests intermediate-term trend pressure persists despite recent stabilization
- Long-term (50% Sell): Moderate sell signal reflects ongoing weakness in the longer-term trend structure
Trend Characteristics: The combination of Weak strength and Weakest direction indicates BioCryst is in a fragile technical environment with limited momentum support heading into the earnings release.
The stock is trading at $8.57, positioned above its 5-day ($8.44), 10-day ($8.13), and 20-day ($8.14) moving averages, suggesting some short-term stabilization. However, the price remains below its 50-day ($8.58), 100-day ($9.10), and 200-day ($8.76) moving averages, confirming the medium- and long-term downtrend identified in the opinion signals.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $8.44 | 50-Day MA | $8.58 |
| 10-Day MA | $8.13 | 100-Day MA | $9.10 |
| 20-Day MA | $8.14 | 200-Day MA | $8.76 |
Key resistance sits immediately overhead at the 50-day moving average of $8.58, while more significant resistance levels cluster at the 200-day ($8.76) and 100-day ($9.10) averages. Support appears near the 20-day average at $8.14. The overall technical setup is cautionary for earnings, with the stock trapped below major moving averages and facing persistent sell signals across all timeframes. A strong earnings beat would need to be substantial enough to break through the 50-day resistance and shift the negative medium-term trend, while a disappointment could send the stock back toward the $8.14 support level or lower.